| abstract |
A pharmaceutical combination or kit comprising as a separate compound 5-ethinyluracil of formula I or a prodrug thereof of formula III which is converted in vivo to 5-ethinyluracil together with 5-fluorouracil of formula II or a prodrug thereof of formula III which is converted in vivo to 5-fluorouracil, for simultaneous or sequential injection, suitable for use in cancer chemotherapy. In formula III, R, R, 1, R, is used. and R.sup.3.n. they are the same or different, and each is a hydrogen atom, a hydroxy group, a halogen atom, an amino group, or a mercapto group. |